Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells

Cancer Letters

Volumn 349, Issue 1, 2014, Pages 51-60

  Chen, Ming Cheng ^a,b   Lee, Nien Hung ^a   Ho, Tsung Jung ^c   Hsu, Hsi Hsien ^d,e   Kuo, Chia Hua ^f   Kuo, Wei Wen ^a   Lin, Yueh Min ^g,h   Tsai, Fuu Jen ^a   Tsai, Chang Hai ⁱ   Huang, Chih Yang ^a,i  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^f UNIVERSITY OF TAIPEI   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^h JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

ⁱ ASIA UNIVERSITY   (Taiwan)

Author keywords

Autophagy; Chemoresistance; CPT 11; Metastasis; NF B

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; WNT PROTEIN; CAMPTOTHECIN; CTNNB1 PROTEIN, HUMAN; DNA TOPOISOMERASE INHIBITOR; EGFR PROTEIN, HUMAN; I KAPPA B KINASE;

ARTICLE; AUTOPHAGY; CANCER CELL; CANCER RESISTANCE; CELL FRACTIONATION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; IC 50; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; ANALOGS AND DERIVATIVES; CELL CYCLE; COLONIC NEOPLASMS; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

AUTOPHAGY; BETA CATENIN; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; I-KAPPA B KINASE; NEOPLASM METASTASIS; NF-KAPPA B; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOPOISOMERASE I INHIBITORS; WNT PROTEINS;

EID: 84901001999     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.023     Document Type: Article

References (44)

1. http://globocan.iarc.fr.
2. Becouarn Y., Ychou M., Ducreux M., Borel C., Bertheault-Cvitkovic F., Seitz J.F., Nasca S., Nguyen T.D., Paillot B., Raoul J.L., Duffour J., Fandi A., Dupont-Andre G., Rougier P. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. 1998, 16:2739-2744.
3. Rothenberg M.L. Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist 2001, 6:66-80.
4. Luqmani Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med. Prin. Pract. 2005, 14:35-48.
5. Hurley L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:188-200.
6. Yim K.L., Cunningham D. Targeted drug therapies and cancer. Recent Results Cancer Res. 2011, 185:159-171.
7. Drewinko B., Romsdahl M.M., Yang L.Y., Ahearn M.J., Trujillo J.M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976, 36:467-475.
8. Xu Y., Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 2002, 13:1841-1851.
9. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
10. Weekes J., Lam A.K.Y., Sebesan S., Ho Y.H. Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J. Gastroenterol. 2009, 15:597-3602.
11. Kaminski B.M., Weigert A., Brune B., Schumacher M., Wenzel U., Steinhilber D., Stein J., Ulrich S. Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemother. Pharm. 2011, 67:1167-1178.
12. Papazisis K.T., Kalemi T.G., Zambouli D., Geromichalos G.D., Lambropoulos A.F., Kotsis A., Boutis L.L., Kortsaris A.H. Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro. Cancer Lett. 2006, 233:255-264.
13. Gregorieff A., Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005, 19:877-890.
14. Sansom O.J., Reed K.R., van de Wetering M., Muncan V., Winton D.J., Clevers H., Clarke A.R. Cyclin D1 is not an immediate target of β-catenin following Apc loss in the intestine. J. Biol. Chem. 2005, 280:28463-28467.
15. Park K.S., Kim S.J., Kim K.H., Kim J.C. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J. Gastroenterol. Hepatol. 2011, 26:391-397.
16. Fournier D.B., Gordon G. COX-2 and colon cancer: potential targets for chemoprevention. J. Cell. Biochem. 2000, Suppl. 34:97-102.
17. Tang C.H. Molecular mechanisms of chondrosarcoma metastasis. Biomedicine 2012, 2:92-98.
18. Pugh S., Thomas G.A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994, 35:675-678.
19. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122:518-523.
20. Li F., Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 1805, 2010:167-180.
21. Jiang X., Takahashi N., Matsui N., Tetsuka T., Okamoto T. The NF-κB activation in lymphotoxin β receptor signaling depends on the phosphorylation of p65 at serine 536. J. Biol. Chem. 2003, 278:919-926.
22. Karin M., Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
23. Hsu S.C., Lin J.H., Weng S.H., Cheuh F.S., Yu C.C., Lu K.W., Wood W.G., Chung J.G. Crude extract of Rheum palmatum inhibits migration and invasion of U-2 OS human osteosarcoma cells by suppression of matrix metalloproteinase-2 and -9. Biomedicine 2013, 3:120-129.
24. Cusack J.C., Liu R., Baldwin A.S. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κBm, nj activation. Cancer Res. 2000, 60:2323-2330.
25. Garg A.K., Buchholz T.A., Aggarwal B.B. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxidants Redox Signaling 2005, 7:1630-1647.
26. Wang C.Y., Mayo M.W., Baldwin A.S. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274:784-787.
27. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med. 1999, 5:412-417.
28. Koizumi F., Kanzawa F., Ueda Y., Koh Y., Tsukiyama S., Taguchi F., Tamura T., Saijo N., Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int. J. Cancer 2004, 108:464-472.
29. Kishida O., Miyazaki Y., Murayama Y., Ogasa M., Miyazaki T., Yamamoto T., Watabe K., Tsutsui S., Kiyohara T., Shimomura I., Shinomura Y. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother. Pharmacol. 2005, 55:584-594.
30. Shimoyama T., Koizumi F., Fukumoto H., Kiura K., Tanimoto M., Saijo N., Nishio K. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 2006, 53:13-21.
31. Veiby O.P., Read M.A. Chemoresistance: impact of nuclear factor (NF)-κB inhibition by small interfering RNA: commentary re J. Guo et al., enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the NF-κB p65 subunit. Clin. Cancer Res. 2004, 10:3262-3264.
32. Fukuyma R., Ng K.P., Cicek M., Kelleher C., Niculaita R., Casey G., Sizemore N. Role of IKK and oscillatory NF-κB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol. Carcinog. 2007, 46:402-413.
33. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
34. Choi K.S. Autophagy and cancer. Exp. Mol. Med. 2012, 44:109-120.
35. Lu S.Z., Harrison-Findik D.D. Autophagy and cancer. World J. Biol. Chem. 2013, 4:64-70.
36. Kenific C.M., Thorburn A., Debnath J. Autophagy and metastasis: another double-edged sword. Curr. Opin. Cell Biol. 2010, 22:241-245.
37. Baldwin A.S. Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol. Rev. 2012, 246:327-345.
38. Fodde R., Smits R. Cancer biology. A matter of dosage. Science 2002, 298:761-763.
39. Lin Y., Bai L., Chen W.J., Xu S.L. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 2010, 14:45-55.
40. Marin J.J.G., de Medina F.S., Castano B., Bujanda L., Romero M.R., Martinez-Augustin O., Moral-Avila R.D., Briz O. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab. Rev. 2012, 44:148-172.
41. Wilson T.R., Longley D.B., Johnston P.G. Chemoresistance in solid tumours. Ann. Oncol. 2006, 17:x315-x324.
42. Cusack J.C., Liu R., Baldwin A.S. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist. Updates 1999, 2:271-273.
43. Marin J.J., Briz O., Monte M.J., Blazquez A.G., Macias R.I. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr. Cancer Drug Targets 2012, 12:402-438.
44. Uetsuka H., Haisa M., Kimura M., Gunduz M., Kaneda Y., Ohkawa T., Takaoka M., Murata T., Nobuhisa T., Yamatsuji T., Matsuoka J., Tanaka N., Naomoto Y. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp. Cell Res. 2003, 289:27-35.